Spero Therapeutics Inc’s recent filing unveils that its Chief Operating Officer Keutzer Timothy unloaded Company’s shares for reported $44099.0 on Feb 05 ’25. In the deal valued at $0.78 per share,56,537 shares were sold. As a result of this transaction, Keutzer Timothy now holds 741,439 shares worth roughly $1.68 million.
Then, Rajavelu Esther sold 20,689 shares, generating $16,137 in total proceeds. Upon selling the shares at $0.78, the CFO & CBO now owns 724,720 shares.
Before that, Shukla Sath sold 155,333 shares. Spero Therapeutics Inc shares valued at $121,160 were divested by the CEO & President at a price of $0.78 per share. As a result of the transaction, Shukla Sath now holds 1,736,883 shares, worth roughly $3.93 million.
Evercore ISI downgraded its Spero Therapeutics Inc [SPRO] rating to an In-line from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who increased its forecast for the stock in late September from “an In-line” to “an Outperform”. Oppenheimer also remained covering SPRO and has decreased its forecast on October 01, 2021 with a “Perform” recommendation from previously “an Outperform” rating. H.C. Wainwright maintained its rating on January 22, 2021. It rated SPRO as “a Buy”.
Price Performance Review of SPRO
On Monday, Spero Therapeutics Inc [NASDAQ:SPRO] saw its stock fall -1.74% to $2.26. Over the last five days, the stock has lost -1.74%. Spero Therapeutics Inc shares have risen nearly 60.28% since the year began. Nevertheless, the stocks have risen 119.42% over the past one year.
How much short interest is there in Spero Therapeutics Inc?
A steep rise in short interest was recorded in Spero Therapeutics Inc stocks on 2025-07-15, dropping by -0.4 million shares to a total of 1.22 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 1.61 million shares. There was a decline of -32.5%, which implies that there is a negative sentiment for the stock.
